Overview
Cagrilintide is classified as a metabolic peptide. Weight loss, appetite reduction, glycemic control.
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
Also known as: NN9838, AM833
Category
Metabolic
Half-Life
168h
Route
SubQ
FDA Status
Not Approved
How Does Cagrilintide Work?
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
At the molecular level, Cagrilintide operates through pathways characteristic of the Metabolic class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Cagrilintide Phase 2 trial for weight management
Lau et al. (Lancet): Phase 2 RCT showing cagrilintide 4.5mg weekly achieved 10.8% weight loss vs 3.0% placebo at 26 weeks, with acceptable safety profile.
Evidence: strong[2]CagriSema (cagrilintide + semaglutide) Phase 2 results
Frias et al. (Lancet): CagriSema combination achieved 15.6% weight loss at 32 weeks in type 2 diabetes patients — superior to either agent alone.
Evidence: strong[3]Amylin analogs in obesity management: mechanism review
Review of amylin's role in energy homeostasis and why dual amylin-calcitonin receptor agonists like cagrilintide represent a new weight loss mechanism distinct from GLP-1.
Evidence: moderateSafety Profile
Generally well-tolerated in Phase 2 trials. Main side effects are GI-related (nausea, vomiting). Novo Nordisk is developing CagriSema (cagrilintide + semaglutide) as next-gen obesity treatment. Research-only peptide.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~25% of users | moderate |
| Diarrhea | ~10% of users | mild |
| Vomiting | ~8% of users | moderate |
| Injection site reaction | ~5% of users | mild |
| Constipation | ~8% of users | mild |
Sourcing Cagrilintide for Research
If you're looking to source Cagrilintide for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Cagrilintide — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.